Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Animals
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Chemotaxis
/ physiology
Female
Humans
Lymphocytes, Tumor-Infiltrating
/ drug effects
Lysophospholipids
/ metabolism
Mice
Mice, Inbred C57BL
Neoplasms
Phosphoric Diester Hydrolases
/ metabolism
Receptors, Lysophosphatidic Acid
/ metabolism
Signal Transduction
/ physiology
Tumor Microenvironment
G protein-coupled receptors
T cells
anti-cancer vaccination
autotaxin
chemorepulsion
immunotherapy
lysophosphatidic acid
melanoma
single-cell RNAseq
tumor microenvironment
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
16 11 2021
16 11 2021
Historique:
received:
23
04
2020
revised:
07
10
2021
accepted:
26
10
2021
entrez:
17
11
2021
pubmed:
18
11
2021
medline:
15
2
2022
Statut:
ppublish
Résumé
Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and T cell motility via LPAR2, yet its actions in the tumor immune microenvironment remain unclear. Here, we show that ATX secreted by melanoma cells is chemorepulsive for tumor-infiltrating lymphocytes (TILs) and circulating CD8
Identifiants
pubmed: 34788605
pii: S2211-1247(21)01495-9
doi: 10.1016/j.celrep.2021.110013
pmc: PMC8761359
mid: NIHMS1757905
pii:
doi:
Substances chimiques
Lysophospholipids
0
Receptors, Lysophosphatidic Acid
0
Phosphoric Diester Hydrolases
EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase
EC 3.1.4.39
lysophosphatidic acid
PG6M3969SG
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110013Subventions
Organisme : BLRD VA
ID : I01 BX005637
Pays : United States
Organisme : CSRD VA
ID : I01 CX001550
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM127211
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL120507
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Z.J. is an employee and shareholder of iOnctura SA, a company developing an ATX inhibitor for use in cancer.
Références
J Exp Med. 2019 Jul 1;216(7):1487-1496
pubmed: 31160320
J Biol Chem. 2009 Jun 26;284(26):17731-41
pubmed: 19386608
Biochim Biophys Acta. 2002 May 23;1582(1-3):45-51
pubmed: 12069809
Int J Mol Sci. 2020 Aug 18;21(16):
pubmed: 32824846
PLoS One. 2011;6(12):e29260
pubmed: 22195035
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Biochim Biophys Acta. 2008 Sep;1781(9):513-8
pubmed: 18621144
J Biol Chem. 2018 Sep 14;293(37):14312-14327
pubmed: 30026231
Trends Cancer. 2017 Nov;3(11):797-808
pubmed: 29120755
J Biol Chem. 2011 Aug 26;286(34):30130-41
pubmed: 21719699
Mol Cancer Res. 2015 Jan;13(1):174-85
pubmed: 25158955
Mol Biol Cell. 2008 Dec;19(12):5435-45
pubmed: 18843048
J Lipid Res. 2019 Nov;60(11):1818-1828
pubmed: 31484695
Pharmacol Ther. 2019 Jan;193:91-98
pubmed: 30048709
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Cancer Discov. 2020 Feb;10(2):185-197
pubmed: 31974169
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
FASEB J. 2019 Mar;33(3):3623-3635
pubmed: 30481488
Immunity. 2021 May 11;54(5):859-874
pubmed: 33838745
J Lipid Res. 2014 Jul;55(7):1192-214
pubmed: 24643338
Trends Immunol. 2015 Dec;36(12):778-787
pubmed: 26596799
Nat Rev Mol Cell Biol. 2011 Sep 14;12(10):674-9
pubmed: 21915140
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
PLoS One. 2014 Jul 08;9(7):e101655
pubmed: 25003200
Bioorg Med Chem Lett. 2016 Nov 15;26(22):5403-5410
pubmed: 27780639
J Mol Med (Berl). 2020 Feb;98(2):179-191
pubmed: 31863151
Elife. 2016 Feb 02;5:e10561
pubmed: 26830463
Cancer Res. 2001 Sep 15;61(18):6938-44
pubmed: 11559573
J Biol Chem. 2019 Jul 19;294(29):11062-11086
pubmed: 31171722
Cancers (Basel). 2018 Mar 15;10(3):
pubmed: 29543710
J Immunol. 1993 Jul 15;151(2):628-36
pubmed: 8393036
Immunol Cell Biol. 2011 Feb;89(2):207-15
pubmed: 21221121
Cancer Res. 2016 May 15;76(10):2921-31
pubmed: 27020860
Nat Commun. 2019 Mar 29;10(1):1405
pubmed: 30926812
Biochem Biophys Res Commun. 1996 Feb 6;219(1):105-10
pubmed: 8619790
J Biol Chem. 2002 Oct 18;277(42):39436-42
pubmed: 12176993
Trends Cancer. 2019 Nov;5(11):704-723
pubmed: 31735289
Sci Rep. 2019 May 15;9(1):7414
pubmed: 31092842
J Lipid Res. 2014 Jun;55(6):1010-8
pubmed: 24548887
Mol Cell Biol. 2006 Jul;26(13):5015-22
pubmed: 16782887
Cell. 2019 Jun 13;177(7):1933-1947.e25
pubmed: 31160049
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Breast Cancer Res. 2018 Sep 5;20(1):108
pubmed: 30185216
Front Immunol. 2018 Oct 29;9:2480
pubmed: 30420855
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Immunol. 2013 Mar 1;190(5):2036-48
pubmed: 23365076
Cancer Cell. 2009 Jun 2;15(6):539-50
pubmed: 19477432
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Nat Immunol. 2008 Apr;9(4):415-23
pubmed: 18327261
Biochim Biophys Acta. 2013 Jan;1831(1):33-41
pubmed: 22902318
Biochem Biophys Res Commun. 2017 Jan 29;483(1):652-657
pubmed: 27993681
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19
pubmed: 22911670
PLoS Biol. 2014 Oct 14;12(10):e1001966
pubmed: 25313567
Nat Rev Cancer. 2003 Aug;3(8):582-91
pubmed: 12894246
J Biol Chem. 2013 Jan 4;288(1):510-9
pubmed: 23150666
J Biol Chem. 1992 Feb 5;267(4):2524-9
pubmed: 1733949
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Nat Struct Mol Biol. 2011 Feb;18(2):198-204
pubmed: 21240271
Nat Commun. 2016 Apr 14;7:11248
pubmed: 27075612
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Discov. 2019 May;9(5):617-627
pubmed: 30837243
Br J Pharmacol. 2020 Sep;177(18):4296-4309
pubmed: 32627178
Nat Med. 2008 Jan;14(1):45-54
pubmed: 18066075
J Biol Chem. 2011 Oct 7;286(40):34654-63
pubmed: 21832043
Front Immunol. 2019 May 28;10:1159
pubmed: 31231367
Nat Struct Mol Biol. 2011 Feb;18(2):205-12
pubmed: 21240269
J Cell Biol. 2002 Jul 22;158(2):227-33
pubmed: 12119361
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
PLoS One. 2010 Mar 17;5(3):e9741
pubmed: 20305819
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765